Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has reached a deal to acquire Optimal Tracers, a radiochemistry development company that offers radiochemistry process development services and research tracers for use in clinical trials, from Sacramento-based Northern California PET Imaging Center (NCPIC).

A highly qualified workforce will be added to Telix as a result of the purchase of Optimal Tracers, and a U.S.-based laboratory and production footprint for clinical trial dosages will be established. The facility is part of the acquisition, and it possesses the necessary radiation and pharmaceutical manufacturing licences to meet the company’s primary needs for diagnostic and therapeutic isotopes for pre-clinical and clinical research. The purchase of Optimal Tracers is in line with Telix’s strategy to increase its vertical integration, strengthen its internal research and radiopharmaceutical development capabilities, and continue to develop the pipeline of novel tracers. Additionally, Optimal Tracers will continue to be a strategic resource for partners’ organisations and pharmaceutical partners who require access to specialised radiochemistry domain knowledge.

Optimal Tracers is a specialised company that offers development services and clinical trial doses to pharmaceutical and biotech companies as well as academic research institutions. It is based in a translational research hub at the University of California, Davis (UCD). With the potential to supply some research items across the whole country, Optimal Tracers is ideally situated to serve top clinical sites along the US West Coast.

Source: Prnewswire